Trending...
- Probate Shepherd® Announces a New Member Probate Attorney in Conroe, TX
- Cancer Survivor Roslyn Franken Marks 30-Year Milestone with Empowering Gift for Women Survivors
- RJ Grimshaw Launches "The AI EDGE" A Practical Guide Where Leadership Meets Innovation
* HMBD ~ Hummingbird Bioscience, a data-driven precision biotherapeutics company, announced a Trials in Progress poster presentation for HMBD-002, a unique anti-VISTA antibody, at the American Society of Clinical Oncology (ASCO) Annual Meeting. The poster will summarize the Phase 1 clinical trial design for HMBD-002.
HMBD-002 is a non-depleting, high-affinity anti-VISTA antibody that possesses key design features enabling robust anti-tumor activity in preclinical models. It is being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination with pembrolizumab. Monotherapy escalation cohorts 1-4 have been completed without dose-limiting toxicities and the trial is currently enrolling cohort 5. Combination escalation is projected to begin in the second half of 2023.
More on illi News
Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience's Chief Scientific Officer said: "VISTA's complex biology makes it a hard-to-drug target, yet we have shown in our preclinical studies that HMBD-002 has potent anti-tumor activity with its unique mechanism of action. In this poster at ASCO, we will display the progress that HMBD-002 has made in Phase 1 trials."
The poster session track is Developmental Therapeutics—Immunotherapy and will be held on June 3rd from 8:00 AM – 11:00 AM CDT at Hall A with Poster Board Number 505b. It is expected that Hummingbird Bioscience will discuss longer term clinical development plans and combination strategies with the wider immuno-oncology community at ASCO.
HMBD-002 has potential to be an important new therapy for VISTA expressing cancers including triple negative breast cancer and non small cell lung cancer.
HMBD-002 is a non-depleting, high-affinity anti-VISTA antibody that possesses key design features enabling robust anti-tumor activity in preclinical models. It is being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination with pembrolizumab. Monotherapy escalation cohorts 1-4 have been completed without dose-limiting toxicities and the trial is currently enrolling cohort 5. Combination escalation is projected to begin in the second half of 2023.
More on illi News
- Multi-Signature Cold Storage: Keyanb Introduces Institutional-Grade Asset Protection for Chilean Crypto Traders
- NKSCX Introduces Zero-Knowledge Proof of Solvency for U.S. Traders Amid $6.5 Billion Fraud Crisis
- New Oasis International Foundation Announces Strategic Partnership Network Across 15 Countries to Advance Community-Led Economic Development
- A Gift for You: Music, Story, and Hope for America: Free Download of The Human Renaissance Album
- New You Smile Dental Implant Center Expands Office
Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience's Chief Scientific Officer said: "VISTA's complex biology makes it a hard-to-drug target, yet we have shown in our preclinical studies that HMBD-002 has potent anti-tumor activity with its unique mechanism of action. In this poster at ASCO, we will display the progress that HMBD-002 has made in Phase 1 trials."
The poster session track is Developmental Therapeutics—Immunotherapy and will be held on June 3rd from 8:00 AM – 11:00 AM CDT at Hall A with Poster Board Number 505b. It is expected that Hummingbird Bioscience will discuss longer term clinical development plans and combination strategies with the wider immuno-oncology community at ASCO.
HMBD-002 has potential to be an important new therapy for VISTA expressing cancers including triple negative breast cancer and non small cell lung cancer.
Filed Under: Business
0 Comments
Latest on illi News
- All About bail Bonds Expands Presence to Serve Houston Families
- Thousands to Ride to L.A. Children's Hospital This Halloween Night
- Essential Living Support Opens First VA Medical Foster Home in Cheyenne, Wyoming
- Stainless Steel Liquatite® Now UL Listed
- Various Measures Intrroduced To And Approved By The Chicago City Council
- Six-Figure Chicks Book Series 96 Authors, 6 Volumes Published to Empower and Mentor Women Nationwide
- LSC Destruction Launches Cutting-Edge Cryptocurrency Scanning to Hard Drive Destruction Services
- Mayor Brandon Johnson Presents The Protecting Chicago Budget
- Hidden Dangers of "Cash for Keys" Offers What Homeowners Should Know Before Agreeing to Leave
- $150 Million Financing Initiates N A S D A Q's First Tether Gold Treasury Combining the Stability of Physical Gold with Blockchain $AURE
- Podcast for Midlife Women Entrepreneurs Celebrates 100th Episode with Rhea Lana's Founder and CEO
- What If Help Could Come Before the Fall?
- Digi 995: Spookyverse — Unlocking the Multiverse of the Digiverse
- ENERICom Channel Releases EPISODE 5 "Pure Michigan in Autumn"
- OddsTrader Examines the NHL Presidents Trophy Curse: Why Regular-Season Success Rarely Leads to Playoff Glory
- Bookmakers Review Launches Betting Insights on NBC's "The Voice: Battle of Champions"
- Coming Up this Weekend on CNBC Mike Milligan Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Chicago: Mayor Brandon Johnson, BACP Announces Request For Proposals For Driver Resource Center
- Mayor Brandon Johnson, Department of Streets and Sanitation, And Chicago Public Library Expand Food Scrap Drop-Off Program To 13 New Library Locations
- Mayor Brandon Johnson Announces the Return Of "Chicago Fall Fest" From Oct. 17-Nov. 2, Featuring Hundreds Of City-Supported Events For Youth and All Residents